Life sciences business launches new product

Listed life sciences business, OptiBiotix Health has launched of WellBiome®, a patented supplement aimed at improving gut health.

The York-based firm which focuses on developing compounds to tackle obesity, high cholesterol, diabetes and skin care, is launching the product as consumers see a renewed focus on health and wellbeing as a result of the current COVID-19 crisis. With a recent NutritionInsights expert roundtable highlighting that topics such as immune health and staying fit & healthy are all at the forefront of minds at present.

WellBiome® is an evolution of the firm’s SlimBiome®, a functional ingredient sold in more than 70 countries and formulated to support weight loss and weight management.

Optibiotix’s new development means it is able to target the digestive health segment of the health and wellbeing industry which accounts for c.US$60 billion.

Stephen O’Hara, CEO of OptiBiotix Health plc, said, “The launch of WellBiome® is another step in OptiBiotix’s strategy of developing functional ingredients which modify the human microbiome to improve health. Consumer understanding and interest in the microbiome is growing rapidly, particularly in the US, and this is creating a market opportunity that is large and expanding. The development of functional ingredients like WellBiome®, backed by science and clinical studies and protected by a broad IP portfolio, allows OptiBiotix and its partners to access this large and growing health and wellbeing trend.”